Icahn School of Medicine at Mount Sinai

The funds will support ZERO Prostate Cancer’s Black Men’s Prostate Cancer Initiative, which provides aid to Black and Brown communities who are at higher risk of prostate cancer.

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

"The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.

An approach combining chemotherapy and immunotherapy could help preserve quality of life.

"If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer," says Matthew Galsky, MD.

"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.

The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Ash Tewari, MBBS, MCh, is Chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai.

“The effect size for adjuvant nivolumab versus placebo across primary, secondary, and exploratory endpoints is all remarkably stable,” says Matthew D. Galsky, MD.

The study also identifies potential ways to make immunotherapy more effective in this setting.